Search results for "Progression"

showing 10 items of 1251 documents

Growth Arrest Specific 1 (Gas1) Gene Overexpression in Liver Reduces the In Vivo Progression of Murine Hepatocellular Carcinoma and Partially Restore…

2015

The prognosis of hepatocellular carcinoma patients is usually poor, the size of tumors being a limiting factor for surgical treatments. Present results suggest that the overexpression of Gas1 (growth arrest specific 1) gene reduces the size, proliferating activity and malignancy of liver tumors. Mice developing diethylnitrosamine-induced hepatocellular carcinoma were subjected to hydrodynamic gene delivery to overexpress Gas1 in liver. This treatment significantly (p < 0.05) reduced the number of large tumors, while the difference in the total number of lesions was not significant. Moreover, the number of carcinoma foci in the liver and the number of lung metastases were reduced. These resu…

MaleCarcinoma Hepatocellularlcsh:MedicineCell Cycle ProteinsGene deliveryBiologyGPI-Linked ProteinsReal-Time Polymerase Chain ReactionTransfectionMiceCell Line TumorGene expressionCarcinomamedicineAnimalslcsh:ScienceLungCell ProliferationRegulation of gene expressionMultidisciplinaryMicroarray analysis techniquesLiver Neoplasmslcsh:RCell cyclemedicine.diseaseMolecular biologyHedgehog signaling pathwayGene Expression Regulation NeoplasticLiverHepatocellular carcinomaDisease ProgressionHydrodynamicslcsh:QResearch ArticlePLoS ONE
researchProduct

Value of Echocardiographic Right Ventricular and Pulmonary Pressure Assessment in Predicting Transcatheter Tricuspid Repair Outcome

2020

The aim of this study was to assess the value of echocardiographic right ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting transcatheter tricuspid edge-to-edge valve repair (TTVR) outcome.RV dysfunction and pulmonary hypertension are associated with poor prognosis and are systematically sought during tricuspid regurgitation evaluation. The value of echocardiographic assessment in predicting TTVR outcome is unknown.Data were taken from the TriValve (Transcatheter Tricuspid Valve Therapies) registry, which includes patients undergoing TTVR at 14 European and North American centers. The primary outcome was 1-year survival free from hospitalization for hear…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)Pulmonary Artery030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicinePrimary outcomePredictive Value of TestsInternal medicinemedicine.arteryVentricular PressureHumansMedicineArterial PressureProspective StudiesRegistries030212 general & internal medicineAgedAged 80 and overHeart FailureHospital readmissionTricuspid valvebusiness.industryRecovery of FunctionMiddle Agedmedicine.diseasePulmonary hypertensionTricuspid Valve Insufficiency3. Good healthPulmonary pressureEuropeTreatment Outcomemedicine.anatomical_structureEchocardiographyHeart failureNorth AmericaPulmonary arteryDisease ProgressionVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma

2017

Objective To determine if perfusion in surgical cavity wall enhancement (SCWE) obtained in early post-treatment MR imaging can stratify time-to-progression (TTP) in glioblastoma. Materials and methods This study enrolled 60 glioblastoma patients with more than 5-mm-thick SCWEs as detected on contrast-enhanced MR imaging after concurrent chemoradiation therapy. Two independent readers categorized the shape and perfusion state of SCWEs as nodular or non-nodular and as having positive or negative perfusion compared with the contralateral grey matter on arterial spin labeling (ASL). The perfusion fraction on ASL within the contrast-enhancing lesion was calculated. The independent predictability…

MaleCentral Nervous Systemlcsh:MedicineContrast MediaKaplan-Meier EstimatePathology and Laboratory MedicineNervous SystemDiagnostic Radiology030218 nuclear medicine & medical imaging0302 clinical medicineFunctional Magnetic Resonance ImagingMedicine and Health SciencesBlastomasMedicinelcsh:ScienceNeurological TumorsBrain MappingMultidisciplinarymedicine.diagnostic_testBrain NeoplasmsRadiology and ImagingChemoradiotherapyCombined Modality TherapyMagnetic Resonance ImagingDacarbazinePerfusionmedicine.anatomical_structureOncologyNeurology030220 oncology & carcinogenesisDisease ProgressionFemaleAnatomymedicine.symptomPerfusionResearch Articlemedicine.drugImaging TechniquesSurgical and Invasive Medical ProceduresNeuroimagingGrey matterResearch and Analysis MethodsLesion03 medical and health sciencesSigns and SymptomsText miningDiagnostic MedicineArterial Spin LabellingImage Interpretation Computer-AssistedTemozolomideHumansAgedTemozolomideSurgical Resectionbusiness.industryProportional hazards modellcsh:RCancers and NeoplasmsBiology and Life SciencesMagnetic resonance imagingmedicine.diseaseLesionslcsh:QSpin LabelsGlioblastomabusinessNuclear medicineGlioblastoma MultiformeNeuroscienceGlioblastomaPLOS ONE
researchProduct

The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia.

2011

AbstractIdentification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated …

MaleChronic lymphocytic leukemiaMICROENVIRONMENTPROGRESSIONCD38GUIDELINESBiochemistryCohort StudiesBone MarrowLYMPHOMAMedicineAged 80 and overHematologyMiddle AgedPrognosisLeukemiaB-CELLSMonoclonalDisease ProgressionBiological MarkersFemaleIGHV@AlgorithmsAdultmedicine.medical_specialtyDISORDERSB-CELLS; CLINICAL-SIGNIFICANCE; CD38 EXPRESSION; LYMPHOMA; CLL; MICROENVIRONMENT; PROGRESSION; GUIDELINES; DISORDERS; DIAGNOSISImmunologyImmunoglobulin light chainDIAGNOSISImmunoglobulin kappa-ChainsImmunoglobulin lambda-ChainsHumansCLINICAL-SIGNIFICANCESurvival analysisAgedbusiness.industryCytogeneticsCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisCD38 EXPRESSIONImmunologyCancer researchImmunoglobulin Light ChainsLymph NodesbusinessSettore MED/15 - Malattie del SangueBiomarkersCLLFollow-Up Studies
researchProduct

A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses

2014

Background: Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its complications. The natural history of complicated coeliac disease is characterised by two different types of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases. Methods: Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and sex- and age-matched coeliac p…

MaleComplicationsSettore MED/09 - Medicina InternaLymphomaSmallGastroenterologyCoeliac diseaseEnteropathy-Associated T-Cell LymphomaIntestine SmallMedicineCeliac diseaseEnteropathyTreatment FailureINTESTINAL T-CELL LYMPHOMAGastroenterologyGLUTEN FREE DIETGeneral Medicinecomplicated coeliac disease; natural history; prognosis;IleitisMiddle AgedPrognosisEnteritisIntestineNatural historyAdult; Aged; Carcinoma; Case-Control Studies; Celiac Disease; Collagenous Sprue; Disease Progression; Enteritis; Enteropathy-Associated T-Cell Lymphoma; Female; Humans; Ileitis; Intestinal Neoplasms; Intestine Small; Jejunal Diseases; Lymphoma B-Cell; Male; Middle Aged; Prognosis; Treatment Failure; Diet Gluten-Freenatural historyGluten-free dietDisease ProgressionEnteropathy-associated T-cell lymphomaFemaleprognosiResearch ArticleCollagenous SprueAdultmedicine.medical_specialtyLymphoma B-CellGlutensSettore MED/12 - GASTROENTEROLOGIAcomplicated coeliac diseasecomplications/drug therapy/mortality Myocytes; celiac diseaseNODiet Gluten-FreeInternal medicineIntestinal NeoplasmsHumanscomplications/drug therapy/mortalitySurvival rateCELIAC DISEASE; Complications; INTESTINAL T-CELL LYMPHOMA; prognosis; GLUTEN FREE DIETAgedcomplications/drug therapy/mortality; Myocytes; celiac diseaseMyocytesbusiness.industryCarcinomaB-CellCase-control studynutritional and metabolic diseasesJejunal DiseasesHepatologymedicine.diseasedigestive system diseasesDietEATLCase-Control StudiesGluten-FreeGluten freebusinessComplicationcoeliac disease
researchProduct

The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population.

2011

Objective: To investigate the symptom of low mood as a predictor of mild cognitive impairment (MCI) and its progression to dementia, taking into account: i) MCI severity, ii) time of assessment, iii) interaction with other factors. Methods: 764 cognitively healthy elderly living in the community, from the Kungsholmen Project. Participants were assessed by direct interview to detect low mood. Subjects were then followed for six years to identify those who developed MCI. People with incident MCI were followed for a further three years to assess progression to dementia. Results: People with low mood at baseline had a 2.7-fold (95% Confidence Interval [CI] 1.9-3.7) increased risk of developing …

MaleDatabases FactualApolipoprotein E4behavioral disciplines and activitiesProdromeCohort Studiesmild cognitive impairmentmental disordersmedicinedepression; epidemiology; mild cognitive impairment; dementiaDementiaHumansCognitive declineAgedSex CharacteristicsMood DisordersCognitive disorderProdromal StageCognitionmedicine.diseaseDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthMoodData Interpretation StatisticaldepressionDisease ProgressionEducational StatusRegression AnalysisSurgeryepidemiologySettore MED/26 - NeurologiaDementiaFemaleNeurology (clinical)AmnesiaPsychologyCognition DisordersCohort studyClinical psychologyFollow-Up StudiesJournal of neurology, neurosurgery, and psychiatry
researchProduct

Intrinsic Expression of Drug Resistance-Associated Factors in Meningiomas

2001

Meningiomas, commonly benign tumors, rarely display aggressive behavior by recurrences and invasion. In addition to surgery, irradiation is beneficial for recurrent, atypical, and malignant meningiomas. The role of chemotherapy, however, remains controversial, although there is evidence that meningiomas respond well to adjuvant chemotherapy. A major obstacle in chemotherapy remains drug resistance with reduced cellular drug accumulation through membrane efflux pumps, drug detoxification, and alterations in drug target specificity. In 84 classic, atypical, and malignant meningiomas, the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (…

MaleDrugHistologyAdolescentmedia_common.quotation_subjectmedicine.medical_treatmentAntineoplastic AgentsDrug resistancePathology and Forensic MedicineMeningeal Neoplasmsotorhinolaryngologic diseasesmedicineHumansMetallothioneinneoplasmsAgedmedia_commonAged 80 and overChemotherapybiologybusiness.industryTopoisomeraseDrug detoxificationMiddle AgedImmunohistochemistryNeoplasm Proteinsnervous system diseasesMedical Laboratory TechnologyDrug Resistance NeoplasmDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleEffluxMeningiomabusinessApplied Immunohistochemistry &amp; Molecular Morphology
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate &amp;gt; 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs &amp;lt; 2 cm. Methods MEN1 patients with 1 or more pNETs &amp;lt; 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by antiviral treatment

2006

The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e5…

MaleEpitope-specific response; HCV/E2 glycoprotein; Human monoclonal antibodies; Therapeutic responseTime FactorsSettore MED/42 - Igiene Generale e ApplicataMolecular ConformationHepacivirusmedicine.disease_causeEpitopePolyethylene GlycolsEpitopeschemistry.chemical_compoundViral Envelope ProteinsAntibody SpecificityHCV/E2 glycoproteinNeutralizing antibodyInfectivitybiologyViral Core ProteinsMiddle AgedHepatitis CEpitope-specific responseTreatment OutcomeInfectious DiseasesDisease ProgressionDrug Therapy CombinationFemaleAntibodyAdultmedicine.drug_classHepatitis C virusMonoclonal antibodyAntiviral AgentsVirusNeutralization TestsVirologyRibavirinmedicineHumansViremiaRibavirintherapeutic responseInterferon-alphaHepatitis C AntibodiesVirologyHuman monoclonal antibodieschemistryImmunologybiology.proteinhuman monoclonal antibodietope-specific response5' Untranslated Regions
researchProduct

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.

2016

Importance The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy–related asthma. Objectives To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. Design, Settings, and Participants Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy–related asthma not well controlled by ICS or combination products, and with HDM allergy–related rhinitis. Key exclusion criteria were FEV 1 less than 70% of predicted…

MaleExacerbationlaw.invention0302 clinical medicineRandomized controlled triallawAdrenal Cortex HormonesSurveys and Questionnaires030212 general & internal medicineRhinitisAged 80 and overbiologyPyroglyphidaeDustGeneral MedicineMiddle AgedTreatment OutcomeAsthma Control QuestionnaireAnesthesiaDisease ProgressionFemaleImmunotherapyTabletsAdultmedicine.medical_specialtyAllergen immunotherapyAdolescentAdministration SublingualPlacebo03 medical and health sciencesYoung AdultDouble-Blind MethodInternal medicineAdministration InhalationmedicineAnimalsHumansAlbuterolAntigens DermatophagoidesAdverse effectAdrenergic beta-2 Receptor AgonistsAsthmaAgedHouse dust mitebusiness.industryAllergensbiology.organism_classificationmedicine.diseaseAsthma030228 respiratory systemImmunoglobulin GQuality of LifebusinessJAMA
researchProduct